NASDAQ$SIGA

SIGA Technologies, Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

SIGA Technologies' financial performance was marked by the first sale of IV TPOXX to the U.S. government and a new contract in the Asia Pacific region.

SIGA Technologies reported a revenue increase for the three months ended March 31, 2022, driven by the first sale of intravenous TPOXX to the U.S. government and a new international contract. The company also declared a special dividend of $0.45 per share.

  • Total revenues increased to $10.5 million compared to $4.8 million in the same period last year.
  • The first sale of intravenous (IV) TPOXX to the U.S. government was completed.
  • A new contract was secured with a jurisdiction in the Asia Pacific region for approximately $3 million of oral TPOXX.
  • The Board of Directors declared a special dividend of $0.45 per share.

Headline financials

Total Revenue

$10.5M

Previous: $4.81M+118.9%
EPS (adj)

-$0.01

Previous: -$0.02+50.0%
Capital Expenditures

$0.00

Previous: -$13.7K+100.0%
Free Cash Flow

-$361K

Previous: -$826K+56.3%
Net Income

-$361K

Previous: -$812K+55.5%
Operating Income

-$1.44M

Previous: -$1.99M+27.7%
Gross Profit

$5.82M

Previous: $4.56M+27.5%
Cash & Equivalents

$153M

Previous: $107M+43.9%

Revenue & EPS history

SIGA Technologies · Revenue · Quarterly

$10.5M

Q1 2022+118.9%vs Q1 2021
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Revenue by segment

SIGA Technologies · $10.5M total across 2 segments · Q1 2022

  • Product Sales
    $7.32M+107.8%
  • R&D Revenues
    $3.22M+149.4%

Forward guidance

SIGA Technologies did not provide specific forward guidance in this earnings report. The company's future performance is subject to various risks and uncertainties, including BARDA contract options, international market development, and the impact of COVID-19.

Tailwinds

  • EMA approval broadens market access
  • New contract with Asia Pacific jurisdiction
  • Increased oral TPOXX procurement contract with Canada
  • Research collaboration with Bioarchitech
  • First sale of IV TPOXX to the U.S. government

Headwinds

  • Risk that BARDA may not exercise all contract options
  • Risk of not completing BARDA contracts on schedule
  • Risk of BARDA contracts being modified or canceled
  • Risk of international biodefense market not developing
  • Risk of COVID-19 impacting SIGA's operations

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

26 / 64 earnings

Positive

+31.9%

Q4 2023

Best reaction

-27.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%-5.5%-8.5%
Q4 2025-3.0%-3.4%-22.8%
Q3 2025-20.2%-24.0%-24.1%
Q1 2025+4.4%+9.0%+10.8%
Q4 2024+7.0%+0.5%+6.4%
Q3 2024-1.9%-8.5%-9.8%
Q2 2024-12.8%-14.3%-9.5%
Q1 2024-27.8%-28.2%-26.7%
Q4 2023+31.9%+49.9%+88.3%
Q3 2023-4.4%-2.2%+16.9%
Q2 2023-3.7%-10.0%-21.9%
Q1 2023+5.1%+1.8%-0.7%
Q4 2022-3.8%-7.8%-13.4%
Q3 2022+7.5%+9.8%+1.1%
Q2 2022+27.4%+24.6%-21.0%
Q1 2022+3.6%+4.0%+60.7%
Q4 2021+3.0%+6.6%+22.4%
Q3 2021-0.7%+0.0%+2.8%
Q2 2021-2.9%-4.0%+9.1%
Q1 2021-0.7%-8.4%-10.4%
Q4 2020+1.7%+9.3%+1.2%
Q3 2020+2.0%+3.4%-0.9%
Q2 2020+14.3%+5.5%-1.9%
Q1 2020-1.4%+1.4%+2.9%
Q4 2019+10.4%+0.4%+0.2%
Q3 2019-3.2%-1.8%-19.8%
Q2 2019+0.2%-1.7%+2.7%
Q1 2019+1.5%-1.3%-12.8%
Q4 2018-4.4%-1.6%-6.3%
Q3 2018+8.4%+5.7%+29.1%
Q2 2018+0.3%+7.7%+1.4%
Q1 2018-0.5%+2.4%-3.9%
Q4 2017-0.6%-7.0%-2.3%
Q3 2017+2.8%-1.1%+3.9%
Q2 2017-1.6%-1.6%-1.9%
Q1 2017-0.3%+0.6%-8.0%
Q4 2016-0.6%+0.0%-4.1%
Q3 2016-5.7%+3.8%+54.8%
Q2 2016+4.5%+4.1%+11.4%
Q1 2016+1.1%
Q4 2015+1.1%
Q3 2015+2.4%
Q2 2015-0.9%
Q1 2015+5.7%
Q4 2014-1.3%
Q3 2014-0.7%
Q2 2014-4.9%
Q1 2014-1.4%
Q4 2013-2.7%
Q3 2013-3.5%
Q2 2013-2.8%
Q1 2011-2.4%
Q4 2012-2.5%
Q3 2012+6.5%
Q2 2012+5.3%
Q1 2012+4.5%
Q4 2011-1.4%
Q4 2009-1.4%
Q3 2010-6.1%
Q3 2011-6.1%
Q2 2011-12.0%
Q2 2010-12.0%
Q4 2010-12.0%
Q1 2010-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro